Co-Diagnostics Announces $5.0 Million Registered Direct Offering Priced At-the-Market
24 Enero 2020 - 7:00AM
Business Wire
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics
company with a unique, patented platform for the development of
molecular diagnostic tests, today announced that it has entered
into definitive agreements with institutional investors for the
purchase of 3,448,278 shares of its common stock, at a purchase
price per share of $1.45, in a registered direct offering priced
at-the-marked under the Nasdaq rules. The closing of the offering
is expected to occur on or about January 28, 2020, subject to the
satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive lead
placement agent for the offering. Maxim Group LLC is acting as
co-placement agent.
The gross proceeds to the Company, before deducting placement
agent fees and other offering expenses, are expected to be
approximately $5.0 million. Co-Diagnostics intends to use the net
proceeds from this offering for further commercialization and
expansion of its infectious disease testing, agrigenomics, and
vector control verticals, acceleration of sales and technology
licensing activities, ongoing development of additional
applications for its technology in markets related to liquid biopsy
and next-gen sequencing, and for working capital and other general
corporate purposes.
The shares of common stock are being offered by Co-Diagnostics
pursuant to a "shelf" registration statement on Form S-3 that was
originally filed on August 14, 2018 and declared effective by the
Securities and Exchange Commission ("SEC") on September 7, 2018,
and the base prospectus contained therein (File No. 333-226835).
The offering of the shares of common stock will be made only by
means of a prospectus supplement that forms a part of the
registration statement.
A final prospectus supplement and accompanying base prospectus
relating to the shares of common stock being offered will be filed
with the SEC. Electronic copies of the final prospectus supplement
and accompanying base prospectus may be obtained, when available,
on the SEC’s website at http://www.sec.gov or by contacting H.C.
Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York,
NY 10022, by phone at 646-975-6996 or e-mail at
placements@hcwco.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such an offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
“believes,” “expects,” “estimates,” “intends,” “may,” “plans,”
“will” and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release include statements regarding the (i) use of funding
proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in certain verticals or markets, (iv)
capital resources and runway needed to advance the Company’s
products and markets, (v) increased sales in the near-term, (vi)
flexibility in managing the Company’s balance sheet, (vii)
anticipation of business expansion, (viii) benefits in research and
worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages and (ix) statements
regarding the offering, the expected gross proceeds from the
offering, the intended use of proceeds and the timing of the
closing of the offering. Forward-looking statements are subject to
inherent uncertainties, risks and changes in circumstances,
including market conditions. Actual results may differ materially
from those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200124005117/en/
Andrew Benson Co-Diagnostics Investor Relations 801-438-1036
investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Co Diagnostics (NASDAQ:CODX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024